Fosrenol

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic Kidney DiseaseGrowthKidney DiseaseHyperphosphatemiaChronic Renal Failure SyndromeNephrolithiasisStage 5 Chronic Kidney DiseaseHypophosphatasia

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

1

Fosrenol

Takeda

Approved

72

Aranesp

Amgen

Preclinical

403

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

164

Uloric

Takeda

Preclinical

35

Glucotrol

Pfizer

Preclinical

16

Vemlidy

Gilead

Preclinical

17

Sovaldi

Gilead

Preclinical

18

Flomax

Sanofi

Preclinical

—9

Miochol

BBausch Health Americas, Inc.

Preclinical

210

Epoetin Beta

Roche

Preclinical

5Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease7 trials

Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease

Completed·Takeda·Phase 2·NCT00234702·84 enrolled

Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease

Completed·GGeoffrey Block·N/A·NCT01341678·15 enrolled

Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease

Completed·MMassachusetts General Hospital·N/A·NCT00438932·16 enrolled

Show 4 more trials

A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis

Completed·Takeda·Phase 2·NCT01696279·63 enrolled

Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5

Terminated·Takeda·Phase 4·NCT00452478·68 enrolled

Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Completed·MMyles Wolf·N/A·NCT00843349·43 enrolled

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

Completed·EEndeavor Health·N/A·NCT01002872·19 enrolled

End-Stage Renal Disease4 trials

Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood

Completed·Takeda·Phase 3·NCT00150566·460 enrolled

Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis

Completed·Takeda·Phase 3·NCT00151931·456 enrolled

Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease

Completed·Takeda·Phase 3·NCT00151918·48 enrolled

Show 1 more trial

Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease

Completed·Takeda·Phase 4·NCT00160121·2,500 enrolled

CAR3 trials

Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy

Completed·Takeda··NCT01130831·66 enrolled

Fosrenol and Phosphorus Balance - Lanthanum Carbonate

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·N/A·NCT01581996·9 enrolled

Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD

Completed·Takeda·Phase 2·NCT01128179·35 enrolled

Dialysis Patients2 trials

Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study

Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT01578200·2,309 enrolled

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT00660530·11 enrolled

Peritoneal Dialysis2 trials

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

Completed·Bayer··NCT01412398·446 enrolled

Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients

Completed·Bayer·Phase 3·NCT01518387·43 enrolled

20 more indications

Growth1 trial

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23

Unknown status·—·Phase 4·NCT01845090·30 enrolled

Hyperphosphatemia1 trial

Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

Unknown status·OOsaka University·Phase 4·NCT02237534·60 enrolled

Bone1 trial

Long-term Effect of Lanthanum Carbonate on Bone

Completed·Takeda··NCT00557323·34 enrolled

Nephrolithiasis1 trial

Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 3·NCT03346369·35 enrolled

Dialysis1 trial

A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.

Completed·Takeda·Phase 3·NCT00150540·93 enrolled

Absorption1 trial

Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers

Completed·Takeda·Phase 1·NCT00875017·31 enrolled

Randomized1 trial

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Completed·DDenver Nephrologists, P.C.·N/A·NCT00785629·148 enrolled

Safety and Efficacy1 trial

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate

Terminated·IIneos Healthcare Limited·Phase 3·NCT00841126·657 enrolled

Tics1 trial

The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers

Completed·Takeda·Phase 1·NCT00925704·41 enrolled

Trial1 trial

Phosphate Lowering in CKD Trial

Completed·VVA Office of Research and Development·Phase 4·NCT02209636·66 enrolled

Nicotinamide1 trial

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

Completed·TThe Cleveland Clinic·Phase 2·NCT02258074·205 enrolled

Calciphylaxis1 trial

Efficacy of Lanthanum Carbonate in Calciphylaxis

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT01289626·12 enrolled

Adult1 trial

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

Completed·Takeda·Phase 1·NCT00880750·72 enrolled

Tolerance1 trial

To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder

Unknown status·GGrand Life Science (Liaoning) Co., Ltd.·Phase 1/2·NCT04440696·48 enrolled

Interaction1 trial

Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders

Completed·SSIGA Technologies·Phase 4·NCT04485039·44 enrolled

Concentration1 trial

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Completed·Bayer·Phase 2·NCT00767637·14 enrolled

Hemodialysis1 trial

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

Completed·Bayer··NCT01419327·3,267 enrolled

Double-blind1 trial

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Completed·Bayer·Phase 3·NCT01514851·259 enrolled

Efficacy1 trial

Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate

Completed·UUniversity of Illinois at Chicago·Phase 1·NCT00458289·12 enrolled

Unspecified4 trials

Different Effects of Non-calcium Phosphate Binders on Serum Calcium

Completed·MMedical University of Lodz·Phase 4·NCT03451019·34 enrolled

Healthy Combine Study

Completed·NNorthwestern University·Phase 1·NCT03136705·39 enrolled

Fosrenol Post-marketing Surveillance in Japan

Completed·Bayer··NCT01955876·343 enrolled

Show 1 more trial

Bioequivalence Study of BAY77-1931 Granule

Completed·Bayer·Phase 1·NCT01053676·59 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News